Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 9, 2005, Pages 5070-5076

  Stowasser, Michael ^a   Sharman, James ^a   Leano, Rodel ^a   Gordon, Richard D ^a   Ward, Gregory ^b   Cowley, Diane ^a   Marwick, Thomas H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CYPROTERONE ACETATE; DEXAMETHASONE; ETHINYLESTRADIOL; LEVONORGESTREL; RENIN;

ADOLESCENT; ADULT; AGE; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE MONITORING; CALIBRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EXPECTATION; FAMILIAL DISEASE; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART VENTRICLE SEPTUM; HUMAN; HYPERTENSION; MALE; MITRAL VALVE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PULSE WAVE; SEX; TISSUE STRUCTURE;

ADOLESCENT; ADULT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CASE-CONTROL STUDIES; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MITRAL VALVE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 24344471007     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0681     Document Type: Article

References (62)

1. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P1990 Myocardial fibrosis and pathological hypertrophy in the rat with renovascular hypertension. Am J Cardiol 65:1G-7G
2. Weber KT, Brilla CG 1991 Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849-1865
3. Young M, Fullerton M, Dilley R, Funder J 1994 Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 93:2578-2583
4. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME 1997 Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 10:1326-1334
5. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL 1993 Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 71:17A-20A
6. Fagard RH, Lijnen PJ, Petrov VV 1998 Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens 12:195-202
7. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE 2000 Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 85:1199-1206
8. Abe M, Hamada M, Matsuoka H, Shigematsu Y, Sumimoto T, HiwadaK1994 Myocardial scintigraphic characteristics in patients with primary aldosteronism. Hypertension 23(Suppl I):I164-I167
9. Napoli C, Di Gregorio F, Leccese M, Abete P, Ambrosio G, Giusti R, Casini A, Ferrara N, De Matteis C, Sibilio G, Donzelli R, Montemarano A, Mazzeo C, Rengo F, Mansi L, Liguori A 1999 Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: The Cross-Sectional Primary Aldosteronism and Heart Italian Multicenter Study. J Invest Med 47:212-221
10. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC 1997 Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95:1471-1478
11. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC 1996 Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039-1045
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717
13. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
14. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM 1992 A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262-265
15. Sutherland DJA, Ruse JL, Laidlaw JC 1966 Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95:1109-1119
16. Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, Gordon RD 1995 Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. J Hypertens 13:1610-1613
17. Stowasser M, Taylor WL, Huggard PJ, Bachmann AW, Gordon RD 1999 Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 84:4031-4036
18. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD 1995 A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Comm 207:565-571
19. Stowasser M, Gartside MG, Gordon RD 1997 A PCR-based method of screening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust N Z J Med 27:685-690
20. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure 2003 The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 289:2560-2572
21. Stowasser M, Gordon RD 2004 The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist 14:267-276
22. Asmar RG, Topouchian JA, Benetos A, Sayegh FA, Mourad JJ, Safar ME 1997 Non-invasive evaluation of arterial abnormalities in hypertensive patients. J Hypertens Suppl 15:S99-S107
23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N 1986 Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450-458
24. Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA 2002 Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation 106:50-56
25. Wickline SA, Thomas III LJ, Miller JG, Sobel BE, Perez JE 1985 The dependence of myocardial ultrasonic integrated backscatter on contractile performance. Circulation 72:183-192
26. Mottram PM, Haluska B, Yuda S, Leano R, Marwick TH 2004 Patients with a hypertensiveresponse to exercise have impaired systolic function without diastolic dysfunction or left ventricular hypertrophy. J Am Coll Cardiol 43:848-853
27. Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH 2003 Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 41:611-617
28. Koyama J, Ray-Sequin PA, Falk RH 2003 Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107:2446-2452
29. Edvardsen T, Skulstad H, Aakhus S, Urheim S, Ihlen H 2001 Regional myocardial systolic function during acute myocardial ischemia assessed by strain Doppler echocardiography. J Am Coll Cardiol 37:726-730
30. Yuda S, Short L, Leano R, Marwick TH 2002 Myocardial abnormalities in hypertensive patients with normal and abnormal left ventricular filling: a study of ultrasound tissue characterization and strain. Clin Sci (Lond) 103:283-293
31. Lucarini AR, Talarico L, Di Bello V, Paterni M, Pedrinelli R, Picano E 1998 Increased myocardial ultrasonic reflectivity is associated with extreme hypertensive left ventricular hypertrophy: a tissue characterization study in humans. Am J Hypertens 11:1442-1449
32. Kozakova M, Buralli S, Palombo C, Bernini G, Moretti A, Favilla S, Taddei S, Salvetti A 2003 Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension 41:230-236
33. Shapiro LM, McKenna WJ 1984 Left ventricular hypertrophy. Relation of structure to diastolic function in hypertension. Br Heart J 51:637-642
34. Douglas PS, Tallant B 1991 Hypertrophy, fibrosis and diastolic function in early canine experimental hypertension. J Am Coll Cardiol 17:530-536
35. Fouad FM 1987 Left ventricular diastolic function in hypertensive patients. Circulation 75(Suppl I):I48 -I55.
36. Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetriou V, Bella JN, Ibsen H, Rokkedal J, Devereux RB 2000 Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIEF study). Am J Cardiol 85:466-472
37. Campbell SE, Diaz-Arias AA, Weber KT 1992 Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press 1:149-156
38. Nishimura H, Kubo S, Nishioka A, Imamura K, Kawamura K, HasegawaM 1985 Left ventricular diastolic function of spontaneously hypertensive rats and its relationship to structural components of the left ventricle. Clin Sci (Lond) 69:571-579
39. Kitamura M, Shimizu M, Ino H, Okeie K, Yamaguchi M, Funjno N, Mabuchi H, Nakanishi I 2001 Collagen remodeling and cardiac dysfunction in patients with hypertrophic cardiomyopathy: the significance of type III and VI collagens. Clin Cardiol 24:325-329
40. Veglio F, Molino P, Cat Genova G, Melchio R, Rabbia F, Grosso T, Martini G, Chiandussi L 1999 Impaired baroreflex function and arterial compliance in primary aldosteronism. J Hum Hypertens 13:29-36
41. O'Regan S, Heitz F, Davignon A 1985 Echocardiographic assessment of left ventricular function in patients with hypokalemia. Miner Electrolyte Metab 11:1-4
42. Foglia PE, Bettinelli A, Tosetto C, Cortesi C, Crosazzo L, Edefonti A, Bianchetti MG 2004 Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). Nephrol Dial Transplant 19:1398-1402
43. Srivastava TN, Young DB 1995 Impairment of cardiac function by moderate potassium depletion. J Card Fail 1:195-200
44. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT 2005 Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111:871-878
45. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG 1992 Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 116:813-820
46. Jamieson A, Slutsker L, Inglis GC, Fraser R, White PC, Connell JMC 1995 Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci (Lond) 88:563-570
47. Stowasser M, Bachmann AW, Huggard PJ, Rossetti TR, Gordon RD 2000 Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and to degree of biochemical disturbance. J Clin Endocrinol Metab 85:2160-2166
48. Stowasser M, Gordon RD 2001 Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78:215-229
49. Skinner SL, Lumbers ER, SymondsEM1969 Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration and substrate. Clin Sci 36:67-76
50. Beckerhoff R, Luetscher JA, Wilkinson R, Gonzales C, Nokes GW 1972 Plasma renin concentration, activity, and substrate in hypertension induced by oral contraceptives. J Clin Endocrinol Metab 34:1067-1073
51. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL 1991 Clinical and pathological diversity of primary aldosteronism including a new familial variety. Clin Exp Pharmacol Physiol 18:283-286
52. Stowasser M, Gordon RD 2003 Primary aldosteronism: from genesis to genetics. Trends Endocrinol Metab 14:310-317
53. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J 2000 Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 85:1863-1867
54. Gordon RD, Klemm SA, Tunny TJ, Stowasser M 1992 Primary aldosteronism: hypertension with a genetic basis. Lancet 340:159-161
55. Young Jr WF 1997 Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 7:213-221
56. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM 2000 High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14:311-315
57. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF 2000 Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85:2854-2859
58. Brilla CG, Matsubara LS, Weber KT 1993 Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A-16A
59. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E 2002 Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143:4828-4836
60. Sato A, Suzuki Y, Saruta T 1999 Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 22:17-22
61. Zannad F, Alla F, Dousset B, Perez A, Pitt B 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive hart failure. Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102:2700-2706
62. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH 2004 Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110:558-565